Prognostic factors for patients with advanced stage serous borderline tumours of the ovary

被引:104
作者
Morice, P
Camatte, S
Rey, A
Atallah, D
Lhommé, C
Pautier, P
Pomel, C
Coté, JF
Haie-Meder, C
Duvillard, P
Castaigne, D
机构
[1] Inst Gustave Roussy, Dept Surg, F-94085 Villejuif, France
[2] Inst Gustave Roussy, Dept Biostat, F-94085 Villejuif, France
[3] Inst Gustave Roussy, Dept Med Oncol, F-94085 Villejuif, France
[4] Inst Gustave Roussy, Dept Pathol, F-94085 Villejuif, France
[5] Inst Gustave Roussy, Dept Radiotherapy, F-94085 Villejuif, France
关键词
borderline tumour; invasive implants; non-invasive implants; ovary; peritoneal implants;
D O I
10.1093/annonc/mdg173
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this study was to determine the prognostic factors for patients with advanced stage, low, malignant potential ovarian tumour (LMPOT). Patients and methods: A retrospective review of 80 patients with serous LMPOT and peritoneal implants treated at or referred to our institution was carried out. Results: Sixty-Five patients had non-invasive implants. Fifteen patients had invasive implants, Twenty-nine patients had stage 11 and 51 patients had stage III disease, Three patients died of evolutive invasive disease and four of complications of treatment. The only prognostic factor of progression to 'evolutive invasive disease' is the pathologic subtype of peritoneal implants, The 5-year rates of evolutive invasive disease in patients with non-invasive implants and invasive implants were 2% and 31%, respectively (P < 0.002), Conclusions: In this series. the only prognostic factor for patients with advanced stage borderline tumour is the type of peritoneal implant. More patients died of the treatment's complications than of the disease itself. The patients' prognosis with non-invasive implants seems to be excellent, and conservative management could be discussed in younger patients.
引用
收藏
页码:592 / 598
页数:7
相关论文
共 37 条
[31]  
RUSSELL P, 1984, CLIN OBSTET GYNAECOL, V11, P259
[32]   Subclassification of serous borderline tumors of the ovary into benign and malignant types - A clinicopathologic study of 65 advanced stage cases [J].
Seidman, JD ;
Kurman, RJ .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (11) :1331-1345
[33]   Ovarian serous borderline tumors: A critical review of the literature with emphasis on prognostic indicators [J].
Seidman, JD ;
Kurman, RJ .
HUMAN PATHOLOGY, 2000, 31 (05) :539-557
[34]  
SOO KLT, 1988, OBSTET GYNECOL, V72, P775
[35]  
Taylor HC, 1929, Surg Gynecol Obs, V48, P204
[36]  
TAZELAAR HD, 1985, OBSTET GYNECOL, V66, P417
[37]   Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: A prospective study [J].
Zanetta, G ;
Rota, S ;
Chiari, S ;
Bonazzi, C ;
Bratina, G ;
Mangioni, C .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2658-2664